Lyra Therapeutics (LYRA) Non-Current Deffered Revenue (2021 - 2025)

Lyra Therapeutics (LYRA) has reported Non-Current Deffered Revenue for 5 consecutive years, with $11.9 million the latest figure, recorded in Q4 2025.

• Non-Current Deffered Revenue for Q4 2025 came in at $11.9 million, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.9 million (changed 0.0% YoY), and the FY2025 annual result was $11.9 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue for Q4 2025 stood at $11.9 million, roughly flat from $11.9 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $14.1 million in Q4 2022, with the low at $1.9 million in Q4 2021.
• A 5-year average of $10.7 million and a median of $11.9 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue soared 630.89% in 2022 and decreased 13.79% in 2023, its largest moves.
• Lyra Therapeutics' Non-Current Deffered Revenue stood at $1.9 million in 2021, then soared by 630.89% to $14.1 million in 2022, then slipped by 13.79% to $12.1 million in 2023, then declined by 2.26% to $11.9 million in 2024, then changed by 0.0% to $11.9 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $11.9 million (Q4 2025), $11.9 million (Q3 2025), and $11.9 million (Q2 2025), per Business Quant data.